Cutera, Inc, a medical device company, designs, develops, manufactures, markets, and services laser and other energy based aesthetics systems worldwide. The company offers enlighten platform, a laser system that is used for tattoo removal, as well as for the treatment of benign pigmented lesions; excel HR platform, a hair removal solution for various skin types; and truSculpt, a high-powered radio frequency platform designed for deep tissue heating.
Read More…
Industry, Sector and Symbol
Industry Electromedical equipment
Sub-IndustryN/A
SectorComputer and Technology
Phone415-657-5500
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$162.72 million
Profitability
Miscellaneous
Employees402
Next Earnings Date11/5/2019 (Estimated)
OptionableOptionable
Cutera (NASDAQ:CUTR) Frequently Asked Questions
What is Cutera's stock symbol?
Cutera trades on the NASDAQ under the ticker symbol "CUTR."
How were Cutera's earnings last quarter?
Cutera, Inc. (NASDAQ:CUTR) released its quarterly earnings results on Thursday, August, 8th. The medical device company reported $0.04 EPS for the quarter, topping the Zacks' consensus estimate of ($0.16) by $0.20. The medical device company had revenue of $47.77 million for the quarter, compared to analyst estimates of $42.08 million. Cutera had a negative return on equity of 69.92% and a negative net margin of 20.49%. Cutera's revenue was up 12.3% compared to the same quarter last year. During the same quarter last year, the firm posted $0.12 earnings per share. View Cutera's Earnings History.
When is Cutera's next earnings date?
What guidance has Cutera issued on next quarter's earnings?
Cutera issued an update on its FY 2019 earnings guidance on Thursday, August, 8th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $165-175 million, compared to the consensus revenue estimate of $169.9 million.
What price target have analysts set for CUTR?
3 analysts have issued twelve-month target prices for Cutera's shares. Their forecasts range from $25.00 to $25.00. On average, they anticipate Cutera's share price to reach $25.00 in the next twelve months. This suggests that the stock has a possible downside of 16.1%. View Analyst Price Targets for Cutera.
What is the consensus analysts' recommendation for Cutera?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cutera in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Cutera.
What are Wall Street analysts saying about Cutera stock?
Here are some recent quotes from research analysts about Cutera stock:
- 1. According to Zacks Investment Research, "Cutera Inc designs, develops, manufactures and markets the CoolGlide family of products for use in laser and other light-based aesthetic applications. The original CoolGlide CV provides permanent hair reduction on all skin types. The second generation CoolGlide Excel incorporated features that added the capability to treat a variety of vascular lesions, which include facial telangiectasia, spider and reticular leg veins. The CoolGlide Vantage added non-ablative skin therapy to the range of applications offered by the system. " (10/17/2019)
- 2. Maxim Group analysts commented, "Market close, CUTR reported better-than-expected 2Q19 revenue, earnings, and gross margin compared to both Maxim and consensus estimates. Due to strong sales during the quarter and higher expected gross margins going forward, we are increasing our 2019 and 2020 revenue and GAAP EPS estimates. Management reiterated 2019 guidance for revenue, gross margins, and adjusted EBITDA, which we believe may now be too conservative in terms of revenue. We are also introducing quarterly estimates for 2020." (8/9/2019)
Has Cutera been receiving favorable news coverage?
News headlines about CUTR stock have trended negative recently, InfoTrie reports. The research firm identifies negative and positive press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Cutera earned a media sentiment score of -2.0 on InfoTrie's scale. They also assigned news stories about the medical device company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for Cutera.
Are investors shorting Cutera?
Cutera saw a drop in short interest in September. As of September 30th, there was short interest totalling 588,000 shares, a drop of 12.4% from the August 30th total of 671,100 shares. Based on an average trading volume of 154,300 shares, the short-interest ratio is presently 3.8 days. Currently, 4.4% of the shares of the company are sold short. View Cutera's Current Options Chain.
Who are some of Cutera's key competitors?
Some companies that are related to Cutera include Natus Medical (BABY), Natus Medical (NTUS), InMode (INMD), AxoGen (AXGN), TransMedics Group (TMDX), Zynex (ZYXI), BioLife Solutions (BLFS), Semler Scientific (SMLR), Viewray (VRAY), Stereotaxis (STXS), BioSig Technologies (BSGM), Rockwell Medical (RMTI), Edap Tms (EDAP), Fonar (FONR) and Second Sight Medical Products (EYES).
What other stocks do shareholders of Cutera own?
Who are Cutera's key executives?
Cutera's management team includes the folowing people:
- Ms. Sandra A. Gardiner, Exec. VP & CFO (Age 53)
- Mr. Larry E. Laber, Exec. VP of Sales - North America (Age 48)
- Mr. Ronald J. Santilli, Exec. Officer (Age 59)
- Mr. Jason Richey, Interim CEO & Chief Operating Officer
- Dr. Michael Karavitis, Exec. VP & Chief Technology Officer
Who are Cutera's major shareholders?
Cutera's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Assenagon Asset Management S.A. (2.30%), State of Alaska Department of Revenue (0.08%) and Stephens Inc. AR (0.08%). Company insiders that own Cutera stock include David A Gollnick, David B Apfelberg, Gregory A Barrett, J Daniel Plants, James A Reinstein, Larry Laber, Miguel Pardos and Timothy J Oshea. View Institutional Ownership Trends for Cutera.
Which major investors are selling Cutera stock?
Which major investors are buying Cutera stock?
CUTR stock was bought by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A. and State of Alaska Department of Revenue. Company insiders that have bought Cutera stock in the last two years include Gregory A Barrett, J Daniel Plants and James A Reinstein. View Insider Buying and Selling for Cutera.
How do I buy shares of Cutera?
Shares of CUTR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Cutera's stock price today?
One share of CUTR stock can currently be purchased for approximately $29.80.
How big of a company is Cutera?
Cutera has a market capitalization of $422.21 million and generates $162.72 million in revenue each year. The medical device company earns $-30,770,000.00 in net income (profit) each year or ($2.23) on an earnings per share basis. Cutera employs 402 workers across the globe.View Additional Information About Cutera.
What is Cutera's official website?
How can I contact Cutera?
Cutera's mailing address is 3240 BAYSHORE BOULEVARD, BRISBANE CA, 94005. The medical device company can be reached via phone at 415-657-5500 or via email at [email protected]
MarketBeat Community Rating for Cutera (NASDAQ CUTR)
MarketBeat's community ratings are surveys of what our community members think about Cutera and other stocks. Vote "Outperform" if you believe CUTR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CUTR will underperform the S&P 500 over the long term. You may vote once every thirty days.
